Frank Gleeson is the founder of Satellos (formerly ICo Therapeutics). Latest round: Seed. Based in Toronto, Ontario, Canada.
Frank Gleeson is the Co-founder and CEO of Satellos Bioscience Inc., a Canadian biotech company focused on treating Duchenne Muscular Dystrophy (DMD) and other degenerative muscle diseases. He previously served as the GlycoNet Chair and oversaw the company's transition from pre-clinical phases to initiating first-in-human safety studies.
Full founder directory · Investor directory · Company funding database · Fundraising library